Global law firm Goodwin has advised investment holding Armira Beteiligungen GmbH & Co. KG ("Armira") on the financing of the partnership with almapharm GmbH & Co. KG ("almapharm"), one of Germany's leading companies in animal nutraceuticals.
almapharm, headquartered in Wildpoldsried, Germany, develops and produces nutraceuticals in the form of healthy food additives for disease prevention and establishes pharmaceutical products for anti-bacterial and anti-inflammatory applications. The company focuses on natural, quality-tested, and certified active ingredients, offering an extensive range of more than 100 nutraceuticals with a broad range of applications.
Munich-based Armira is a leading investment holding company focusing on direct equity investments in medium-sized, profitable family businesses and ambitious growth companies in the DACH region, Northern Italy, and beyond. Armira is backed by an exclusive investor base of families, entrepreneurs, and entrepreneurial capital, fostering trusted partnerships with a long-term horizon.
Goodwin's transaction team was led by partner Winfried M. Carli and counsel Andreas Breu (both Private Equity/Finance, Munich) and included associates Marius Garnatz and Rebecca Stöcklein (both Private Equity/Finance, Frankfurt), partner Oded Schein (Tax/Munich) and transaction lawyer Rina Omura (Private Equity/Finance, Munich).